Dr. Roberto Pinelli

Dr. Roberto Pinelli
CEO and Scientific Director of the Switzerland Eye Research Institute in Lugano

Dr Roberto Pinelli is the CEO and Scientific Director of the Switzerland Eye Research Institute in Lugano, which he founded eight years ago. His current main focus is on PBM for the treatment of dry AMD, using it in synergy with nutraceuticals, to which he dedicates his research with great scientific passion: the use of select phytochemicals, featured in numerous scientific publications, has proved to be a highly effective support for PBM, particularly in the treatment of dry macular degeneration. Throughout his professional career he has dealt with many and varied clinical cases, obtaining highly satisfactory results in terms of disease stability. The success of his working method has led him to research into the modulation of light frequencies not only in relation to the eyes, but for the treatment of the whole body. His interest in neuroscience, a field to which he is increasingly drawn, stems from his intuition that one can use the eye as a portal to reach other parts of the body.

His research is increasingly wide-ranging, and he has authored, also in collaboration with other international institutes of translational and regenerative medicine, the following scientific publications, the latest in the field of neuroscience:

  • “A Re-Appraisal of Pathogenic Mechanisms Bridging Wet and Dry Age-Related Macular DegenerationLeads to Reconsider a Role for Phytochemicals”, International Journal of Molecular Sciences, 2020
  • “The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal”, CellR4, 2020
  • “Nutraceuticals for dry age-related macular degeneration: a case report based on novel pathogenic and morphological insights”. Archives Italiennes de Biologie. A Journal of Neuroscience, 2020
  • “Photobiomodulation shows the power of light”. Ophthalmology Times, 2020
  • “Harnessing the power of light in dry age-related macular degeneration”. Opthalmology Times Europe, 2020
  • “Measurement of drusen and their correlation with visual symptoms in patients affected by age-related macular degeneration”, Archives Italiennes de Biologie. A Journal of Neuroscience, 2021
  • “Retinal Degeneration Following Chronic Administration of the Parkisonism-Inducing Neurotoxin MPTP”. Archives Italiennes de Biologie. A Journal of Neuroscience, 2021

DON'T MISS OUT - REGISTER NOW FOR PBM2021!
REGISTER NOW

© 2021 North American Association for Photobiomodulation Therapy; World Association for Photobiomodulation Therapy.

All rights reserved | Privacy and cookie policy.

LiveChat will be activated on September 27th, and wll remain fully functional until October 11th, 2021

You are being transferred to Easychair—our Abstract Submission platform—where you will be prompted to create an account. Once you have created an account, follow the simple prompts to submit your abstract. Please indicate your preference for podium presentation, or if you prefer a poster presentation, include the word "Poster" after your keywords.

If your abstract is accepted, you will be required to register for the meeting before presenting.

Further registration instructions will be posted to this website when they come available.

CONTINUE TO EASYCHAIR